About Maxion
Maxion has engineered a new class of biologics by harnessing knottins, one of nature’s most potent modulators of ion channels and G protein-coupled receptors (GPCR). Combining a knottin with an antibody’s advantageous drug properties, we are developing transformative treatments that reach new levels of specificity and durability for patients with ion channel and GPCR-driven diseases. Initially focused on immunological diseases, heart disorders and chronic pain, our pipeline of proprietary KnotBody® molecules will access targets that have long remained beyond the reach of biologics.
Situated at Unity Campus in Cambridge, UK, Maxion Therapeutics fosters a dynamic and forward-thinking work environment underpinned by our scientific founders, who are trailblazers in antibody engineering. Led by our CEO, Dr Arndt Schottelius, our experienced leadership team boasts a stellar track record. Dr Schottelius has held senior leadership positions, successfully advancing therapeutics from research to late-stage clinical development and building valuable portfolios of drug candidates and pharma partnerships. Maxion’s co-founders, Dr John McCafferty (CTO) and Dr Aneesh Karatt Vellatt (CSO), previously co-founded IONTAS, and together invented KnotBody® technology. Dr McCafferty is also renowned for co-inventing antibody phage display, which contributed to the 2018 Nobel Prize in Chemistry (awarded to his co-inventor Sir Gregory Winter), and co-founding Cambridge Antibody Technology.
About the Role
We are seeking a highly organised and proactive (Associate) Programme Manager – Discovery to support the execution of Discovery Research initiatives. This is an on-site position based at our Cambridge (Unity Campus) location, requiring close collaboration with cross-functional scientific teams. Reporting to the Director of Programme Management, the role also acts as a strategic partner to the Chief Scientific Officer (CSO).
The successful candidate will function as a central coordination point for Discovery activities, ensuring efficient information flow, strong programme governance, and adherence to timelines. The role combines programme management discipline with scientific understanding to enable effective delivery of early-stage drug discovery projects.
The ideal candidate will be detail-oriented, proactive, and able to synthesise complex scientific and operational information into clear insights for leadership.